USPTO Establishes Visiting Professionals Program; First Visiting Professional Issues CRS Report on Hatch-Waxman Issues

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

[author: Donald Zuhn]

USPTO Seal

In February, the U.S. Patent and Trademark Office announced the establishment of the Thomas Alva Edison Visiting Professionals Program, which is designed to tap into the expertise of distinguished IP professionals and academics who are able to devote up to six months of service to the Office on a full time basis.  The Office also announced that the first Edison Professional will be Georgetown Law Professor John R. Thomas.  The Office noted that since 1999, Prof. Thomas has served as a Visiting Scholar with the Congressional Research Service (CRS), where he assisted members of Congress and their staff during the enactment of both the American Inventors Protection Act (AIPA) and Leahy-Smith America Invents Act (AIA).  Prof. Thomas also clerked for Chief Judge Helen Nies of the Court of Appeals for the Federal Circuit.

Thomas, John

As a Visiting Scholar with the CRS, Prof. Thomas (at left) recently prepared a report for Congress entitled "Patent Infringement and Experimental Use Under the Hatch-Waxman Act: Current Issues."  In that report, Prof. Thomas notes that "[r]eflecting its compromise nature, the [Hatch-Waxman Act] both provides an exemption for patent infringement (for FDA regulatory compliance activities) and creates a new infringing act (the filing of certain ANDAs by generic firms)."  In particular, the Act contains one provision (35 U.S.C. § 271(e)(1)) that creates a statutory "safe harbor" exempting someone from a patent infringement claim based on acts reasonably related to seeking marketing approval from the FDA, and a second provision (35 U.S.C. § 271(e)(2)) that creates a "somewhat artificial" act of infringement allowing a brand-name company to enforce its patent against a generic competitor that has filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification.

The report indicates that recent judicial developments have involved both provisions.  With respect to § 271(e)(1), the report notes that in Classen Immunotherapies, Inc. v. Biogen Idec, 659 F.3d 1057 (Fed. Cir. 2011), the Federal Circuit concluded that § 271(e)(1) is "directed to premarketing approval of generic counterparts before patent expiration."  The report concludes that "[i]n view of this holding, activities not associated with the preparation of an NDA or ANDA are not shielded by the safe harbor, even though they lead to information that must be reported to the FDA."  However, "[b]ecause 35 U.S.C. §271(e)(1) does not expressly restrict its scope to premarketing approval efforts," the report notes that the holding in Classen "has been the subject of considerable discussion."  In addition, as Judge Moore noted in her dissent in Classen, the Supreme Court has consistently construed the safe harbor in an expansive manner.  The report, however, acknowledges that "[i]f 35 U.S.C. §271(e)(1) were to apply to post-approval activities, then a potentially broad swath of activity could be conducted free of the patent system."

With respect to § 271(e)(2), the report indicates that while this section does not expressly state that brand-name companies must explicitly identify patents to the FDA prior to asserting those patents under § 271(e)(2), "the Supreme Court has suggested that such identification is a predicate for litigation."  Nevertheless, the report points out that "[t]he courts have yet to rule definitively on this point."  Noting that "[w]hether a cause of action under 35 U.S.C. §271(e)(2) is predicated upon a paragraph IV certification or not holds notable consequences for the Hatch-Waxman system," the report suggests that if such a certification is not required, then the filing of an ANDA could lead to a claim of infringement for a patents that is not listed in the Orange Book.  The report notes that the issue was most recently acknowledged (but left unresolved) by the Federal Circuit in Abraxis Bioscience Inc. v. Navinta LLC, 625 F.3d 1359 (Fed. Cir. 2010).  However, the report suggests that "[t]his issue may yet be placed before the courts in the future."

The report concludes that should Congress decide that it needs to intervene and revise the two provisions, it "could stipulate whether 35 U.S.C. §271(e)(1) applies to acts that occur following the award of FDA marketing approval or not," and "also explicitly state whether 35 U.S.C. §271(e)(2) establishes a cause of action for infringement of patents that have not been listed in the Orange Book and therefore were not the subject of a paragraph IV certification."

Hat tip to Greg Aharonian for making the CRS report available via his e-mail newsletter.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.